VITREOSOLVE^®

Vitreoretinal Technologies, Inc. is in clinical development of Vitreosolve^® for preventative treatment of diabetic retinopathy, a vascular disease that affects nearly 10% of the US population.
READ MORE >>

Vitreosolve^® vitreous liquefaction is used as an adjunct to pars plana vitrectomy surgery.
READ MORE >>